Sexually Transmitted Diseases, Viral
Welcome,         Profile    Billing    Logout  
 122 Companies   161 Products   161 Products   116 Mechanisms of Action   12 Trials   2436 News 


«12345678910111213...4950»
  • ||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Trial completion, Trial primary completion date:  Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (clinicaltrials.gov) -  Apr 4, 2017   
    P2,  N=149, Completed, 
    N=412 --> 0 | Completed --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Mar 2016
  • ||||||||||  Enrollment closed, Trial primary completion date, Adherence:  MedCHEC: Medications for Chronic HIV: Education and Collaboration (clinicaltrials.gov) -  Mar 31, 2017   
    P=N/A,  N=348, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2012 --> Jun 2013
  • ||||||||||  Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
    Trial completion:  Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth (clinicaltrials.gov) -  Mar 28, 2017   
    P4,  N=371, Completed, 
    Trial primary completion date: Feb 2017 --> Jun 2017 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Phase classification, Enrollment change:  CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin (clinicaltrials.gov) -  Mar 24, 2017   
    P,  N=8, Completed, 
    Phase classification: P2 --> P=N/A Active, not recruiting --> Completed | Phase classification: PN/A --> P | N=12 --> 8
  • ||||||||||  Trial completion:  Vitamin D Supplementation in HIV (clinicaltrials.gov) -  Mar 17, 2017   
    P2/3,  N=58, Completed, 
    Active, not recruiting --> Completed | Phase classification: PN/A --> P | N=12 --> 8 Active, not recruiting --> Completed
  • ||||||||||  Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
    Phase classification:  PRO 140 for Human Immunodeficiency Virus Infection (clinicaltrials.gov) -  Mar 9, 2017   
    P2a,  N=0, Withdrawn, 
    Active, not recruiting --> Completed | N=82 --> 50 | Trial primary completion date: Sep 2011 --> Jul 2010 Phase classification: P2 --> P2a
  • ||||||||||  Phase classification:  Preventative Misconception Intervention (clinicaltrials.gov) -  Mar 3, 2017   
    P=N/A,  N=120, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jul 2010 Phase classification: P1/2 --> P=N/A
  • ||||||||||  rifampicin / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Immune Activation and Drug Absorption in HIV-Infected Patients (clinicaltrials.gov) -  Mar 3, 2017   
    P=N/A,  N=7, Completed, 
    Initiation date: Feb 2017 --> Feb 2012 Not yet recruiting --> Completed | N=10 --> 7 | Trial primary completion date: Dec 2014 --> Mar 2016
  • ||||||||||  Phase classification:  A Novel Method to Determine HIV Incidence Among Youth (clinicaltrials.gov) -  Mar 1, 2017   
    P=N/A,  N=440, Completed, 
    Not yet recruiting --> Completed | N=10 --> 7 | Trial primary completion date: Dec 2014 --> Mar 2016 Phase classification: P1/2 --> P=N/A
  • ||||||||||  Trial completion, Adherence:  Typology of Adherence in Adolescents: Phase II (clinicaltrials.gov) -  Feb 28, 2017   
    P2,  N=1200, Completed, 
    Phase classification: P4 --> P=N/A Recruiting --> Completed
  • ||||||||||  Trial completion:  A Novel Method to Determine HIV Incidence Among Youth (clinicaltrials.gov) -  Feb 28, 2017   
    P=N/A,  N=440, Completed, 
    No longer recruiting --> Completed No longer recruiting --> Completed
  • ||||||||||  Trial completion:  4-Day-A-Week Treatment Plan for HIV Infected Adolescents (clinicaltrials.gov) -  Feb 28, 2017   
    P4,  N=31, Completed, 
    No longer recruiting --> Completed No longer recruiting --> Completed
  • ||||||||||  naltrexone / Generic mfg.
    Trial completion, Trial primary completion date:  Clinical Trial to Reduce Drinking in Women With HIV (clinicaltrials.gov) -  Feb 27, 2017   
    P3,  N=194, Completed, 
    No longer recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2016
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Trial completion, Enrollment change, Trial primary completion date:  Safety Study of Isentress (clinicaltrials.gov) -  Feb 23, 2017   
    P3,  N=149, Completed, 
    Active, not recruiting --> Completed | N=400 --> 99 Not yet recruiting --> Completed | N=200 --> 149 | Trial primary completion date: Sep 2011 --> Aug 2012
  • ||||||||||  Hiltonol (poly-ICLC) / Oncovir
    Trial primary completion date:  Enhancement by Poly-ICLC During HIV-1 Infection (clinicaltrials.gov) -  Feb 14, 2017   
    P1/2,  N=15, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016 Trial primary completion date: Aug 2016 --> Apr 2017
  • ||||||||||  Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread? (clinicaltrials.gov) -  Feb 14, 2017   
    P=N/A,  N=6, Completed, 
    Trial primary completion date: Aug 2016 --> Apr 2017 Recruiting --> Completed | N=20 --> 6 | Initiation date: Dec 2013 --> Jan 2013 | Trial primary completion date: Mar 2015 --> Dec 2014
  • ||||||||||  Trial completion:  Anti-HIV Medications for People Recently Infected With HIV (clinicaltrials.gov) -  Feb 6, 2017   
    P4,  N=180, Completed, 
    Recruiting --> Completed | N=20 --> 6 | Initiation date: Dec 2013 --> Jan 2013 | Trial primary completion date: Mar 2015 --> Dec 2014 Recruiting --> Completed
  • ||||||||||  Trial completion, Trial primary completion date:  Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy (clinicaltrials.gov) -  Feb 2, 2017   
    P=N/A,  N=402, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jul 2012 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014
  • ||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  IPERGAY: On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men (clinicaltrials.gov) -  Feb 1, 2017   
    P3,  N=400, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014 Suspended --> Completed | N=1900 --> 400 | Trial primary completion date: Mar 2016 --> Jun 2016
  • ||||||||||  mefloquine / Generic mfg.
    Trial completion:  The Effect of Malaria on Disease Progression of HIV/AIDS (clinicaltrials.gov) -  Jan 26, 2017   
    P=N/A,  N=197, Completed, 
    Suspended --> Completed | N=1900 --> 400 | Trial primary completion date: Mar 2016 --> Jun 2016 Active, not recruiting --> Completed
  • ||||||||||  methamphetamine / Generic mfg.
    Trial completion, Trial primary completion date:  Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users (clinicaltrials.gov) -  Jan 23, 2017   
    P=N/A,  N=502, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2015
  • ||||||||||  Trial primary completion date:  RHIVA: Reducing HIV in Adolescents (clinicaltrials.gov) -  Jan 19, 2017   
    P2,  N=3217, Completed, 
    Phase classification: P2 --> P2b Trial primary completion date: Dec 2012 --> Aug 2014